Comparison · NCT04788511-sae
Semaglutide 2.4 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Semaglutide 2.4 mg vs Placebo: serious adverse events. Trial comparisons, record NCT04788511-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04788511-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.133 | 0.0973 | 0.179 | wilson | |
| Risk in group 2 | 0.267 | 0.217 | 0.323 | wilson | |
| Risk difference, group 1 minus group 2 | -0.134 | -0.2 | -0.066 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.499 | 0.345 | 0.72 | log | |
| Odds ratio, group 1 over group 2 | 0.422 | 0.269 | 0.66 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Semaglutide 2.4 mg than on Placebo | 7.47 | 4.99 | 15.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Semaglutide 2.4 mg | Participants with obesity (BMI ≥30.0 kg/m\^2) related heart failure with preserved ejection fraction received semaglutide 2.4 mg once weekly by subcutaneous injection (in the abdomen, thigh or upper arm). Participants initially received 0.25 mg of semaglutide. The dose was then escalated every fourth week with increments of 0.25 mg for 16 weeks until the target dose of 2.4 mg was reached. The treatment period was 52 weeks. | 35 | 263 | EG000 |
| Group 2 | Placebo | Participants with obesity (BMI ≥30.0 kg/m\^2) related heart failure with preserved ejection fraction received placebo once weekly by subcutaneous injection (in the abdomen, thigh or upper arm) for 52 weeks. The dose escalation and maintenance of placebo matched that of semaglutide. | 71 | 266 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From baseline (week 0) to end of trial (week 57)
Source ClinicalTrials.gov
Trial
- Title
- Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
- NCT number
- NCT04788511
- Phases
- PHASE3
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
- Results first posted
- 2024-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04788511?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04788511-sae